/NFX.L
NFX.L Stock - Nuformix plc
Healthcare|BiotechnologyLSE
$0.24+0.42%
+$0.00 (+0.42%) • Dec 22
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.61
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.27
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NFX.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.24 – $0.24
TARGET (TP)$0.28
STOP LOSS$0.22
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.47
52W High$0.56
52W Low$0.04
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $50,000 | $195,550 | $535,000 |
| Gross Profit | N/A | $-36,749 | $11,329 | $86,717 | $201,405 |
| Gross Margin | N/A | N/A | 22.7% | 44.3% | 37.6% |
| Operating Income | $-3,647,053 | $-618,648 | $-1,270,270 | $-1,373,980 | $-918,180 |
| Net Income | $-3,641,487 | $-572,978 | $-1,108,993 | $-1,253,497 | $-756,376 |
| Net Margin | N/A | N/A | -2218.0% | -641.0% | -141.4% |
| EPS | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
Company Overview
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NFX.LBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q2 2025
EPS Surprise History
Q4 21
No data
Q3 22
No data
Q1 23
No data
Q2 23
No data
Q1 24
No data
Q2 24
No data
Q1 25
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 30, 2026 | — | — | — | — |
Q1 2026 | Jan 27, 2026 | — | — | — | — |
Q2 2025 | May 2, 2025 | — | $-0.00 | — | — |
Q1 2025 | Jan 29, 2025 | — | $-0.00 | — | — |
Q2 2024 | Jun 18, 2024 | — | $0.00 | — | — |
Q1 2024 | Jan 3, 2024 | — | $-0.00 | — | — |
Q2 2023 | May 22, 2023 | — | $-0.00 | — | — |
Q1 2023 | Jan 24, 2023 | — | $0.00 | — | — |
Q3 2022 | Jul 28, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 14, 2021 | — | $-0.00 | — | — |
Q3 2021 | Jul 15, 2021 | — | $-0.00 | — | — |
Q4 2020 | Dec 22, 2020 | — | $-0.00 | — | — |
Q3 2020 | Jul 23, 2020 | — | $-0.00 | — | — |
Q4 2019 | Dec 24, 2019 | — | $-0.00 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.00 | — | — |
Q4 2018 | Dec 20, 2018 | — | $-0.00 | — | — |
Q3 2018 | Jul 26, 2018 | — | $0.00 | — | — |
Q4 2017 | Oct 14, 2017 | — | $0.00 | — | — |
Q1 2017 | Mar 31, 2017 | — | $-0.00 | — | — |
Q3 2016 | Sep 30, 2016 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about NFX.L
What is NFX.L's current stock price?
Nuformix plc (NFX.L) is currently trading at $0.24 per share. The stock has moved +0.42% today.
What is the analyst price target for NFX.L?
No analyst price targets are currently available for this stock.
What sector is Nuformix plc in?
Nuformix plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the LSE exchange.
What is NFX.L's market cap?
Nuformix plc has a market capitalization of $0.01 billion, making it a small-cap company.
Does NFX.L pay dividends?
No, Nuformix plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCIZ.L
Cizzle Biotechnology Holdings Plc
$1.55
Mkt Cap: $0.6B
FUM.L
Futura Medical plc
$1.08
Mkt Cap: $0.3B
GENF.L
Genflow Biosciences plc
$1.80
Mkt Cap: $0.9B
GENI.L
GENinCode plc
$2.45
Mkt Cap: $0.7B
IXI.L
IXICO plc
$11.75
Mkt Cap: $1.1B
OBD.L
Oxford BioDynamics Plc
$0.23
Mkt Cap: $0.5B
OPTI.L
OptiBiotix Health Plc
$6.75
Mkt Cap: $0.7B
TCF.L
Theracryf Plc
$0.20
Mkt Cap: $0.4B
TRX.L
Tissue Regenix Group plc
$7.25
Mkt Cap: $0.5B
VRCI.L
Verici Dx plc
$0.78
Mkt Cap: $1.2B
Explore stocks similar to NFX.L for comparison